Abstract:Purpose: While the occurrence of colitis during immune checkpoint inhibitor (ICI) treatment is recognized as a sign of robust immune activation and correlates with better oncological outcomes, the long-term impact of ICI-mediated colitis on the colonic mucosa has not been studied. We thus aim to describe the colonoscopy and histology findings in patients at a follow-up time of ≥ 6 months post initial colitis event. Methods: This retrospective analysis included adult cancer patients diagnosed with ICI colitis at a tertiary cancer center between October 2013 and June 2020. The study group included patients diagnosed with immune mediated colitis who had also undergone a follow up colonoscopy or flex sigmoidoscopy. The control group was patients exposed to ICI without immune mediated colitis. We reported patients' colitis clinical course, treatment, outcomes, and endoscopic and histologic features at diagnosis and at follow-up time of ≥ 6 months. Results: Total 39 patients met the study criteria, with 82% being male, and 35.8% having melanoma. Most patients received a combination of CTLA-4 and PD-1/L1 inhibitors (82%). On initial endoscopic evaluation, inflammation without ulceration was reported in 76.9% of patients and active inflammation on histologic examination in 79.3% of patients. Most patients (79.4%) received corticosteroids, and 56.4% received add-on selective immunosuppressive therapy. Four patients received fecal microbiota transplantation. On follow-up, new incidence of colonic polyps was reported in 51.2% of patients, including adenomas in 33.3% among the colitis patients with median follow up duration of 12 months. The incidence of adenoma polyps 12 months after the colitis event was significantly higher compared to the control group without colitis based on the time-to-event analysis (p=0.041). Conclusion: At a median follow up of 12 months after their initial colitis diagnosis, 51.2% of the patients had new incidence of colonic polyps, including a third with adenoma, at a significantly higher incidence than the control group without colitis. Studies with larger sample sizes are needed to further define the long-term impact of colitis and its treatments on colon health and to refine recommendations for surveillance of colonic adenomas and colorectal cancer.

S1303 Initial Histologic Presentations of Immune Checkpoint Inhibitor Colitis and Their Differential Disease Outcomes

S1271 A Retrospective Study of Treatment Options for Checkpoint-Inhibitor Colitis and Their Impact on Disease Outcomes

S1302 The When, the Where, and the How: Temporal and Quantitative Trends in Fecal Calprotectin Levels and the Implications for Checkpoint-Inhibitor Colitis

Follow-Up Biopsies in Gastrointestinal Immune Checkpoint Inhibitor Toxicity May Show Markedly Different Inflammatory Patterns Than Initial Injury

New strategies in the diagnosis and treatment of immune-checkpoint inhibitor-mediated colitis

S1161 Gastrointestinal Infection Prior to Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk for Checkpoint-Inhibitor Colitis

S295 The Impact of Fecal Diversion on Immune Checkpoint Inhibitor Adverse GI Toxicities

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Immune Checkpoint Inhibitor-Associated Colitis: from Mechanism to Management

Histopathologic Features of Unmasked Inflammatory Bowel Disease Following Immune Checkpoint Inhibitor Therapy in Colon Biopsies

S3034 Refractory Immune Checkpoint Inhibitor-Associated Colitis: Case Report

Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis

Immune checkpoint inhibitor-induced colitis complicated with inflammatory intestinal obstruction: a case report and literature review

Colon Adenoma After Diagnosis of Immune Checkpoint Inhibitor-mediated Colitis

Immune Checkpoint Inhibitor-Induced Colitis with Endoscopic Evaluation in Chinese Cancer Patients: a Single-Centre Retrospective Study

Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis

Novel endoscopic scoring system for immune mediated colitis: A Multicenter Retrospective Study of 674 Patients

Immune checkpoint inhibitor-induced diarrhea and colitis: an overview

Immune checkpoint inhibitor–related colitis in patients on immunotherapy for cancer

Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis

Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment